H B Zech1, S Laban2, P Schafhausen3, L Bussmann4, C Betz4, C-J Busch4. 1. Klinik und Poliklinik für Hals‑, Nasen‑, Ohrenheilkunde, Kopf-Hals-Chirurgie und -Onkologie, Universitätsklinikum Hamburg Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland. h.zech@uke.de. 2. Kopf-Hals-Tumorzentrum des Universitätsklinikums Ulm, Klinik für Hals‑, Nasen‑, Ohrenheilkunde und Kopf-Hals-Chirurgie, Universitätsklinikum Ulm, Frauensteige 12, 87070, Ulm, Deutschland. 3. Kopf-Hals-Tumorzentrum des Universitären Cancer Center Hamburg, II. Medizinische Klinik und Poliklinik (Onkologie, Hämatologie, Knochenmarktransplantation mit Abteilung für Pneumologie), Universitätsklinikum Hamburg Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland. 4. Klinik und Poliklinik für Hals‑, Nasen‑, Ohrenheilkunde, Kopf-Hals-Chirurgie und -Onkologie, Universitätsklinikum Hamburg Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland.
Abstract
BACKGROUND: The contributions presented at this year's ASCO conference on treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) focused on systemic therapies, as in recent years. Two phase III studies-TPExtreme and Keynote-048-are expected to change clinical practice in first-line treatment of R/M-HNSCC. MATERIALS AND METHODS: Abstracts and presentations from this year's ASCO Annual Meeting on R/M-HNSCC were screened and checked for clinical relevance. RESULTS:TPExtreme, a randomized phase III trial, could show less toxicity and similar overall survival in patients treated with docetaxel, cisplatin, and cetuximab (TPEx regimen) compared to standard first-line therapy with the Extreme regimen (cisplatin, 5‑fluorouracil [5-FU], cetuximab), albeit failing its endpoint of significantly improved survival. The randomized phase III Keynote-048 study could show a significant survival benefit in all patients treated with pembrolizumab, 5‑FU, and cis-/carboplatin compared to Extreme. When selected patients (PD-L1 CPS ≥1 and ≥20) were treated with pembrolizumab monotherapy, they showed increased overall response rates in contrast to patients treated with Extreme. CONCLUSION: Based on the results of Keynote-048, pembrolizumab ± chemotherapy gained FDA approval as first-line treatment for R/M-HNSCC in the USA. Approval in Europe is expected soon and will probably have a strong impact on clinical routine.
RCT Entities:
BACKGROUND: The contributions presented at this year's ASCO conference on treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) focused on systemic therapies, as in recent years. Two phase III studies-TPExtreme and Keynote-048-are expected to change clinical practice in first-line treatment of R/M-HNSCC. MATERIALS AND METHODS: Abstracts and presentations from this year's ASCO Annual Meeting on R/M-HNSCC were screened and checked for clinical relevance. RESULTS: TPExtreme, a randomized phase III trial, could show less toxicity and similar overall survival in patients treated with docetaxel, cisplatin, and cetuximab (TPEx regimen) compared to standard first-line therapy with the Extreme regimen (cisplatin, 5‑fluorouracil [5-FU], cetuximab), albeit failing its endpoint of significantly improved survival. The randomized phase III Keynote-048 study could show a significant survival benefit in all patients treated with pembrolizumab, 5‑FU, and cis-/carboplatin compared to Extreme. When selected patients (PD-L1 CPS ≥1 and ≥20) were treated with pembrolizumab monotherapy, they showed increased overall response rates in contrast to patients treated with Extreme. CONCLUSION: Based on the results of Keynote-048, pembrolizumab ± chemotherapy gained FDA approval as first-line treatment for R/M-HNSCC in the USA. Approval in Europe is expected soon and will probably have a strong impact on clinical routine.
Entities:
Keywords:
Adverse effects; Head and neck neoplasms; Neoplasm metastatis; Neoplasm recurrence, local; R/M-HNSCC
Authors: Ezra E W Cohen; Denis Soulières; Christophe Le Tourneau; José Dinis; Lisa Licitra; Myung-Ju Ahn; Ainara Soria; Jean-Pascal Machiels; Nicolas Mach; Ranee Mehra; Barbara Burtness; Pingye Zhang; Jonathan Cheng; Ramona F Swaby; Kevin J Harrington Journal: Lancet Date: 2018-11-30 Impact factor: 79.321
Authors: Alexander Drilon; Theodore W Laetsch; Shivaani Kummar; Steven G DuBois; Ulrik N Lassen; George D Demetri; Michael Nathenson; Robert C Doebele; Anna F Farago; Alberto S Pappo; Brian Turpin; Afshin Dowlati; Marcia S Brose; Leo Mascarenhas; Noah Federman; Jordan Berlin; Wafik S El-Deiry; Christina Baik; John Deeken; Valentina Boni; Ramamoorthy Nagasubramanian; Matthew Taylor; Erin R Rudzinski; Funda Meric-Bernstam; Davendra P S Sohal; Patrick C Ma; Luis E Raez; Jaclyn F Hechtman; Ryma Benayed; Marc Ladanyi; Brian B Tuch; Kevin Ebata; Scott Cruickshank; Nora C Ku; Michael C Cox; Douglas S Hawkins; David S Hong; David M Hyman Journal: N Engl J Med Date: 2018-02-22 Impact factor: 91.245
Authors: Jan B Vermorken; Jan Stöhlmacher-Williams; Irina Davidenko; Lisa Licitra; Eric Winquist; Cristian Villanueva; Paolo Foa; Sylvie Rottey; Krzysztof Skladowski; Makoto Tahara; Vasant R Pai; Sandrine Faivre; Cesar R Blajman; Arlene A Forastiere; Brian N Stein; Kelly S Oliner; Zhiying Pan; Bruce A Bach Journal: Lancet Oncol Date: 2013-06-06 Impact factor: 41.316
Authors: Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison Journal: N Engl J Med Date: 2016-10-08 Impact factor: 91.245
Authors: J Guigay; J Fayette; A F Dillies; C Sire; J N Kerger; I Tennevet; J P Machiels; S Zanetta; Y Pointreau; L Bozec Le Moal; S Henry; A Schilf; J Bourhis Journal: Ann Oncol Date: 2015-06-24 Impact factor: 32.976
Authors: J B Vermorken; F Peyrade; J Krauss; R Mesía; E Remenar; T C Gauler; U Keilholz; J P Delord; P Schafhausen; J Erfán; T H Brümmendorf; L Iglesias; U Bethe; C Hicking; P M Clement Journal: Ann Oncol Date: 2014-03 Impact factor: 32.976
Authors: Ezra E W Cohen; R Bryan Bell; Carlo B Bifulco; Barbara Burtness; Maura L Gillison; Kevin J Harrington; Quynh-Thu Le; Nancy Y Lee; Rom Leidner; Rebecca L Lewis; Lisa Licitra; Hisham Mehanna; Loren K Mell; Adam Raben; Andrew G Sikora; Ravindra Uppaluri; Fernanda Whitworth; Dan P Zandberg; Robert L Ferris Journal: J Immunother Cancer Date: 2019-07-15 Impact factor: 13.751